Physician profile
Jordan Michael Mast
NPI 1518211051
$246,843.65
in general payments reported to CMS, 2019-2025
85 companies · $88K in 2025
The $88K reported for 2025 was more than what 99% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2021: $42K · 2022: $32K · 2023: $25K · 2024: $60K · 2025: $88K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $86K · Food and Beverage: $34K · Consulting Fee: $27K · Travel and Lodging: $14K · Honoraria: $6,000 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $5,090 · Education: $50.41.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $85,990.00 |
| Food and Beverage | $34,264.58 |
| Consulting Fee | $27,390.00 |
| Travel and Lodging | $14,496.67 |
| Honoraria | $6,000.00 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $5,090.00 |
| Education | $50.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $91,824.21 | 2021-2025 | |
| Eisai INC. | $36,876.74 | 2021-2025 | |
| Lilly USA, LLC | $24,577.70 | 2021-2025 | Kisunla, Amyvid, Emgality |
| Allergan, INC. | $22,037.64 | 2021-2022 | |
| Pfizer INC. | $13,635.18 | 2021-2025 | |
| Axsome Therapeutics, INC. | $8,118.39 | 2025 | Symbravo |
| Lundbeck LLC | $6,033.40 | 2021-2025 | Vyepti, Rexulti |
| Genzyme Corporation | $4,678.23 | 2021-2025 | |
| Amgen INC. | $3,709.20 | 2021-2025 | Uplizna, Tezspire, Aimovig |
| Eli Lilly and Company | $3,198.00 | 2022 | |
| Biogen, INC. | $2,226.47 | 2021-2025 | Tysabri, Vumerity, Skyclarys |
| Ucb, INC. | $2,225.84 | 2021-2025 | Rystiggo, Fintepla, Briviact |
| Acadia Pharmaceuticals INC | $1,749.45 | 2021-2025 | Nuplazid, Daybue |
| Celgene Corporation | $1,622.11 | 2021-2025 | Zeposia |
| Novartis Pharmaceuticals Corporation | $1,569.43 | 2021-2025 |
Show all 85 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $1,353.30 | 2021-2025 | Ultomiris, Soliris |
| Emd Serono, INC. | $1,282.00 | 2021-2025 | Mavenclad, Mavenclad |
| Neurocrine Biosciences, INC. | $1,225.58 | 2021-2025 | Ingrezza, Ongentys |
| Tg Therapeutics, INC. | $1,172.41 | 2023-2025 | |
| Jazz Pharmaceuticals INC. | $1,139.13 | 2021-2025 | |
| Sk Life Science, INC. | $1,098.39 | 2021-2025 | Xcopri |
| Biohaven Pharmaceuticals, INC. | $1,092.65 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $1,084.39 | 2021-2025 | Austedo Xr, Ajovy, Austedo Xr |
| E.R. Squibb & Sons, L.L.C. | $896.65 | 2021-2025 | Zeposia |
| Genentech USA, INC. | $857.67 | 2021-2025 | Ocrevus, Ocrevus Zunovo, Enspryng |
| Biohaven Pharmaceutical Holding Company Ltd. | $809.21 | 2022 | |
| Mdd US Operations, LLC | $768.82 | 2021-2025 | Gocovri, Gocovri |
| Biodelivery Sciences International, INC. | $750.00 | 2021 | |
| Merz Pharmaceuticals, LLC | $711.56 | 2022-2025 | Xeomin, Inbrija |
| Neurelis, INC. | $708.02 | 2021-2025 | Valtoco |
| Argenx US, INC. | $564.75 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Impel Pharmaceuticals INC. | $549.13 | 2022-2023 | Trudhesa |
| Grt US Holding, INC. | $527.31 | 2021-2022 | |
| Ani Pharmaceuticals, INC. | $435.84 | 2022-2025 | Purified Cortrophin Gel |
| Ipsen Biopharmaceuticals, INC | $430.52 | 2022-2025 | Dysport |
| Acorda Therapeutics, INC | $336.51 | 2021-2024 | Inbrija |
| Mallinckrodt Hospital Products INC. | $320.65 | 2021-2025 | Acthar |
| Supernus Pharmaceuticals, INC. | $308.05 | 2021-2022 | |
| Abbott Laboratories | $300.66 | 2021-2025 | Infinity |
| Livanova USA, INC. | $278.45 | 2021-2024 | Vns Therapy Sentiva Model 1000 Generator |
| Grifols USA, LLC | $251.08 | 2021-2025 | Gamunex-C, Xembify |
| Vanda Pharmaceuticals INC. | $248.87 | 2024-2025 | Ponvory |
| Tanabe Pharma America, INC. | $210.09 | 2022-2025 | Radicava |
| Amneal Pharmaceuticals LLC | $186.46 | 2021-2025 | Crexont |
| Otsuka America Pharmaceutical, INC. | $162.61 | 2023-2024 | Rexulti, Nuedexta |
| Octapharma USA, INC. | $157.64 | 2022-2023 | Panzyga |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $149.74 | 2025 | Rexulti |
| Alnylam Pharmaceuticals INC. | $139.31 | 2022-2024 | Onpattro |
| Avadel Cns Pharmaceuticals, LLC | $136.60 | 2024 | Lumryz |
| Averitas Pharma INC. | $132.09 | 2023 | Qutenza |
| Csl Behring | $130.98 | 2021-2024 | Hizentra |
| Sobi, INC | $123.27 | 2021-2022 | |
| Upsher-Smith Laboratories LLC | $123.21 | 2021-2023 | |
| Collegium Pharmaceutical, INC. | $121.82 | 2022 | |
| Cycle Pharmaceuticals INC | $115.04 | 2025 | Tascenso Odt, Bafiertam |
| Janssen Pharmaceuticals, INC | $105.14 | 2021-2022 | |
| Banner Life Sciences, LLC | $95.52 | 2021-2024 | |
| Kedrion Biopharma, INC. | $93.88 | 2022-2024 | Rhogam Ultra-Filtered Plus, Albuked, Gammaked |
| Catalyst Pharmaceuticals, INC. | $88.87 | 2023-2025 | Fycompa |
| Janssen Biotech, INC. | $87.62 | 2025 | |
| Boston Scientific Corporation | $78.40 | 2024-2025 | Vercise, General - Therapies |
| Scilex Pharmaceuticals INC. | $77.26 | 2022-2024 | Ztlido |
| Takeda Pharmaceuticals U.S.A., INC. | $67.89 | 2024 | Hyqvia |
| Adamas Pharmaceuticals, INC. | $60.89 | 2021 | |
| Ge Healthcare | $56.50 | 2024-2025 | |
| Tonix Medicines, INC. | $55.32 | 2024 | Zembrace Symtouch |
| Harmony Biosciences LLC | $51.67 | 2023-2024 | Wakix |
| Almatica Pharma LLC | $44.65 | 2021 | |
| Idorsia Pharmaceuticals US INC | $42.51 | 2023 | Quviviq |
| C2n Diagnostics, LLC | $40.28 | 2025 | Precivityad2 |
| Avion Pharmaceuticals | $36.31 | 2023 | Dhivy |
| Kyowa Kirin, INC. | $36.13 | 2021-2023 | Nourianz |
| Horizon Therapeutics Plc | $25.42 | 2023 | Uplizna |
| Nevro Corp. | $24.71 | 2022 | |
| Astrazeneca Pharmaceuticals Lp | $23.13 | 2022 | |
| Greenwich Biosciences, INC. | $22.09 | 2021 | |
| Janssen Scientific Affairs, LLC | $21.60 | 2024 | |
| Life Molecular Imaging Ltd | $20.88 | 2025 | Neuraceq |
| Xeris Pharmaceuticals, INC. | $20.12 | 2023 | Keveyis |
| Vertex Pharmaceuticals Incorporated | $19.81 | 2025 | |
| Akcea Therapeutics, INC. | $18.63 | 2021 | |
| Insightec,INC | $16.85 | 2023 | Exablate |
| Kedrion Biopharma INC. | $16.12 | 2021 | |
| Sonex Health, INC. | $13.39 | 2025 | Sx-One Microknife |
| Bio Products Laboratory USA, INC. | $9.61 | 2023 | Coagadex, Gammaplex |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$1,110.00 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jordan Mast listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.